AIDS Malignancies Training and Research International Program (AMTRIP)

艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)

基本信息

  • 批准号:
    10618999
  • 负责人:
  • 金额:
    $ 29.15万
  • 依托单位:
  • 依托单位国家:
    美国
  • 项目类别:
  • 财政年份:
    2022
  • 资助国家:
    美国
  • 起止时间:
    2022-02-01 至 2026-03-31
  • 项目状态:
    未结题

项目摘要

PROJECT SUMMARY/ABSTRACT HIV/AIDS is at epidemic proportions in Zambia, where approximately 1.2 million people – representing about 12% of the country's adult population – are infected. Concomitant with this epidemic, the widespread availability of free anti-retroviral treatment in-country has increased the lifespan of HIV-1 infected individuals, resulting in prolonged chronic immunosuppression and increased occurrence of HIV-associated cancers. However, in-country efforts to prevent, diagnose, and manage cancer in Zambia have been hindered by a lack of laboratory facilities, insufficient cancer research infrastructure, and a shortage of trained personnel. Recognizing these critical gaps, the University of Zambia School of Medicine, the University Teaching Hospitals, and the University of Nebraska-Lincoln leveraged the success of a previous Fogarty partnership to establish the AIDS Malignancies Training and Research International Program (AMTRIP) in collaboration with a new lead partner, the Cancer Diseases Hospital (CDH). This unique program aims to enhance Zambia's cancer research infrastructure and capacity by training Zambian biomedical researchers and health care providers in laboratory techniques and research methodology related to basic cancer biology, molecular genomics, and bioinformatics. Now in its fifth year, AMTRIP has made significant strides by providing intensive long-term graduate degree training and short- and medium-term technical training for a diverse group of 25 trainees; hosting workshops for over 300 health care professionals; successfully transitioning trainees into mentorship roles; adapting program activities to meet the needs of trainees and the rapidly changing cancer research landscape; and leveraging partnerships with other D43 programs to expand the program's impact. Building on these accomplishments, this renewal application seeks to further enhance cancer research capacity in Zambia by: 1) continuing to provide long-term academic instruction and research experiences for eight current master's and three current PhD students in Zambia and recruiting four additional master's and two additional PhD students; 2) providing medium-term (six months to one year) technical training for trainees in topics related to molecular pathology, cancer biology, bioinformatics and genomics; and 3) delivering short- term training (less than three months) and technical workshops (3-5 days) designed to enhance basic, clinical, implementation, genomics, bioinformatics, and behavioral cancer research in collaboration with other regional partners and programs. Expected outcomes of this renewal include the graduation of eight current master's and three current PhD candidates; recruitment and training of an additional four master's and two PhD students in relevant cancer research fields; the transition of trainees into mentorship roles; enhanced infrastructure at Zambian institutions, including the completion of a CDH laboratory renovation; and expanded partnerships with other D43 programs. Given current progress and anticipated renewal outcomes, AMTRIP is on track to transition program leadership to the next generation of cancer researchers in a future renewal.
项目概要/摘要 艾滋病毒/艾滋病在赞比亚已呈流行病,该国约有 120 万人——相当于 该国 12% 的成年人口受到感染。伴随着这次疫情的爆发, 国内免费抗逆转录病毒治疗的可用性延长了 HIV-1 感染者的寿命, 导致长期的慢性免疫抑制和艾滋病毒相关癌症的发生率增加。 然而,赞比亚国内预防、诊断和治疗癌症的努力因缺乏 实验室设施不足、癌症研究基础设施不足以及训练有素的人员短缺。 认识到这些关键差距,赞比亚大学医学院、大学教学 医院和内布拉斯加大学林肯分校利用之前福格蒂合作伙伴关系的成功, 与以下机构合作建立艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP) 新的主要合作伙伴是癌症疾病医院 (CDH)。这一独特的计划旨在增强赞比亚的 通过培训赞比亚生物医学研究人员和医疗保健来提高癌症研究基础设施和能力 与基础癌症生物学、分子生物学相关的实验室技术和研究方法的提供者 基因组学和生物信息学。 AMTRIP 现已进入第五个年头,通过提供密集的服务,取得了重大进展。 为25人的多元化群体提供长期研究生学位培训和短期和中期技术培训 实习生;为 300 多名医疗保健专业人员举办研讨会;成功将学员转入 指导角色;调整计划活动以满足学员和快速变化的癌症的需求 研究景观;利用与其他 D43 计划的合作伙伴关系来扩大该计划的影响。 在这些成就的基础上,这一更新应用程序旨在进一步加强癌症研究 赞比亚的能力通过:1)继续提供长期的学术指导和研究经验 赞比亚目前有八名硕士生和三名博士生,并另外招募四名硕士和博士生 另外两名博士生; 2)为学员提供中期(六个月至一年)技术培训 与分子病理学、癌症生物学、生物信息学和基因组学相关的主题; 3)提供短期 学期培训(少于三个月)和技术研讨会(3-5天)旨在增强基础、临床、 与其他区域合作实施、基因组学、生物信息学和行为癌症研究 合作伙伴和计划。此次更新的预期成果包括八名现有硕士毕业 以及三名现任博士生;招聘和培训另外四名硕士和两名博士 相关癌症研究领域的学生;受训者转变为导师角色;增强型 赞比亚机构的基础设施,包括完成 CDH 实验室改造;并扩大了 与其他 D43 计划的合作伙伴关系。鉴于目前的进展和预期的更新成果,AMTRIP 有望在未来的更新中将项目领导权移交给下一代癌症研究人员。

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

Chipepo Kankasa其他文献

Chipepo Kankasa的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('Chipepo Kankasa', 18)}}的其他基金

AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
  • 批准号:
    10405562
  • 财政年份:
    2022
  • 资助金额:
    $ 29.15万
  • 项目类别:
AIDS Malignancies Training and Research International Program (AMTRIP)
艾滋病恶性肿瘤培训和研究国际计划 (AMTRIP)
  • 批准号:
    10542913
  • 财政年份:
    2022
  • 资助金额:
    $ 29.15万
  • 项目类别:
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
赞比亚艾滋病恶性肿瘤诊断和发病机制计划 (ZAMDAPP)
  • 批准号:
    9404820
  • 财政年份:
    2017
  • 资助金额:
    $ 29.15万
  • 项目类别:
Admin-Core-001
管理核心-001
  • 批准号:
    10496102
  • 财政年份:
    2017
  • 资助金额:
    $ 29.15万
  • 项目类别:
Zambia AIDS Malignancies Diagnosis and Pathogenesis Program Supplement
赞比亚艾滋病恶性肿瘤诊断和发病机制计划补充资料
  • 批准号:
    10381368
  • 财政年份:
    2017
  • 资助金额:
    $ 29.15万
  • 项目类别:
The Zambia AIDS Malignancies Diagnosis and Pathogenesis Program (ZAMDAPP)
赞比亚艾滋病恶性肿瘤诊断和发病机制计划 (ZAMDAPP)
  • 批准号:
    10242673
  • 财政年份:
    2017
  • 资助金额:
    $ 29.15万
  • 项目类别:

相似海外基金

RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    10219039
  • 财政年份:
    2020
  • 资助金额:
    $ 29.15万
  • 项目类别:
RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9981476
  • 财政年份:
    2019
  • 资助金额:
    $ 29.15万
  • 项目类别:
IGF::OT::IGF RESEARCH SUPPORT SERVICES FOR THE DIVISION OF ACQUIRED IMMUNODEFICIENCY SYNDROME
IGF::OT::IGF 针对获得性免疫缺陷综合症分类的研究支持服务
  • 批准号:
    9364184
  • 财政年份:
    2016
  • 资助金额:
    $ 29.15万
  • 项目类别:
Human Immunodeficiency Virus (HIV) and Acquired Immunodeficiency Syndrome (AIDS) in Saskatchewan- Where are we now and what does the future hold?
萨斯喀彻温省的人类免疫缺陷病毒(HIV)和获得性免疫缺陷综合症(艾滋病)——我们现在在哪里以及未来会怎样?
  • 批准号:
    236932
  • 财政年份:
    2011
  • 资助金额:
    $ 29.15万
  • 项目类别:
    Miscellaneous Programs
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554155
  • 财政年份:
    1991
  • 资助金额:
    $ 29.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6766860
  • 财政年份:
    1991
  • 资助金额:
    $ 29.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW COMMI
获得性免疫缺陷综合症研究审查委员会
  • 批准号:
    3554156
  • 财政年份:
    1991
  • 资助金额:
    $ 29.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6256640
  • 财政年份:
    1991
  • 资助金额:
    $ 29.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME RESEARCH REVIEW
获得性免疫缺陷综合症研究综述
  • 批准号:
    2063342
  • 财政年份:
    1991
  • 资助金额:
    $ 29.15万
  • 项目类别:
ACQUIRED IMMUNODEFICIENCY SYNDROME REVIEW
获得性免疫缺陷综合症审查
  • 批准号:
    6091256
  • 财政年份:
    1991
  • 资助金额:
    $ 29.15万
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了